STOCK TITAN

IDG-Accel group in CASI (NASDAQ: CASI) drops below 5% stake

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

CASI Pharmaceuticals’ major shareholders updated their ownership disclosure in this Amendment No. 7 to Schedule 13D. The IDG-Accel affiliated funds and related reporting persons collectively report beneficial ownership of 915,850 CASI ordinary shares, representing 4.5% of the 20,548,273 ordinary shares outstanding as of September 30, 2025. Individual reporting person Quan Zhou reports beneficial ownership of 992,638 ordinary shares, or 4.8%, including 76,788 shares issuable upon option exercise. The amendment states that each reporting person ceased to be the beneficial owner of more than five percent of CASI’s ordinary shares on September 30, 2025, primarily due to an increase in the company’s total shares outstanding. The filers also note they have not engaged in transactions in CASI securities during the past sixty days and include detailed allocations of sole and shared voting and dispositive powers among the IDG-Accel entities and the two individuals.

Positive

  • None.

Negative

  • None.





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
The value in lines 7 and 9 represents 855,222 ordinary shares of the Issuer held by the Reporting Person. The value in lines 8 and 10 represents 60,628 ordinary shares of the Issuer held by IDG-Accel China III Investors L.P. ("IDG-Accel Investors"). Percent of Class Represented by Amount in Row (11) is based on 20,548,273 ordinary shares of the Issuer outstanding as of September 30, 2025, as disclosed in the Issuer's current report on Form 6-K filed with the Securities and Exchange Commission on November 14, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
The value in lines 7 and 9 represents 60,628 ordinary shares of the Issuer held by the Reporting Person. The value in lines 8 and 10 represents 855,222 ordinary shares of the Issuer held by IDG-Accel China Growth Fund III L.P. ("IDG-Accel Growth"). Percent of Class Represented by Amount in Row (11) is based on 20,548,273 ordinary shares of the Issuer outstanding as of September 30, 2025, as disclosed in the Issuer's current report on Form 6-K filed with the Securities and Exchange Commission on November 14, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
The value in lines 7 and 9 represents 855,222 ordinary shares of the Issuer held by IDG-Accel Growth. The Reporting Person is the sole general partner of IDG-Accel Growth. By virtue of this affiliation, the Reporting Person may be deemed to have sole voting and dispositive power with respect to all these securities. The value in lines 8 and 10 represents 60,628 ordinary shares of the Issuer held by IDG-Accel Investors. The Reporting Person has the same general partner, IDG-Accel China Growth Fund GP III Associates Ltd. as IDG-Accel Investors. By virtue of this affiliation, the Reporting Person may be deemed to be under common control with IDG-Accel Investors and thus share voting and dispositive power with respect to these shares. Percent of Class Represented by Amount in Row (11) is based on 20,548,273 ordinary shares of the Issuer outstanding as of September 30, 2025, as disclosed in the Issuer's current report on Form 6-K filed with the Securities and Exchange Commission on November 14, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
The value in lines 7 and 9 represents (i) 855,222 ordinary shares of the Issuer held by IDG-Accel Growth; and (ii) 60,628 ordinary shares of the Issuer held by IDG-Accel Investors. The Reporting Person is the ultimate general partner of both IDG-Accel Growth and IDG-Accel Investors. By virtue of this affiliation, the Reporting Person may be deemed to have voting and dispositive power with respect to all these shares. Percent of Class Represented by Amount in Row (11) is based on 20,548,273 ordinary shares of the Issuer outstanding as of September 30, 2025, as disclosed in the Issuer's current report on Form 6-K filed with the Securities and Exchange Commission on November 14, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
The value in lines 8 and 10 represents (i) 855,222 ordinary shares of the Issuer held by IDG-Accel Growth; and (ii) 60,628 ordinary shares of the Issuer held by IDG-Accel Investors. The Reporting Person and Quan Zhou are directors and shareholders of IDG-Accel China Growth Fund GP III Associates Ltd., the ultimate general partner of IDG-Accel Growth and IDG-Accel Investors, thus may be deemed to share voting and dispositive power with respect to all these shares. Percent of Class Represented by Amount in Row (11) is based on 20,548,273 ordinary shares of the Issuer outstanding as of September 30, 2025, as disclosed in the Issuer's current report on Form 6-K filed with the Securities and Exchange Commission on November 14, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
The value in lines 7 and 9 represents 76,788 ordinary shares of the Issuer issuable upon exercise of certain options issued by the Issuer to Quan Zhou. The value in lines 8 and 10 represents (i) 855,222 ordinary shares of the Issuer held by IDG-Accel Growth; and (ii) 60,628 ordinary shares of the Issuer held by IDG-Accel Investors. The Reporting Person and Chi Sing Ho are directors and shareholders of IDG-Accel China Growth Fund GP III Associates Ltd., the ultimate general partner of IDG-Accel Growth and IDG-Accel Investors, thus may be deemed to share voting and dispositive power with respect to all these shares. Percent of Class Represented by Amount in Row (11) is based on 20,548,273 ordinary shares of the Issuer outstanding as of September 30, 2025, as disclosed in the Issuer's current report on Form 6-K filed with the Securities and Exchange Commission on November 14, 2025.


SCHEDULE 13D


IDG-Accel China Growth Fund III L.P.
Signature:/s/ Chi Sing Ho on behalf of IDG-Accel China Growth Fund GP III Associates Ltd., ultimate General Partner of IDG-Accel China Growth Fund III L.P.
Name/Title:Chi Sing Ho / Authorized Signatory
Date:01/20/2026
IDG-Accel China III Investors L.P.
Signature:/s/ Chi Sing Ho on behalf of IDG-Accel China Growth Fund GP III Associates Ltd., General Partner of IDG-Accel China III Investors L.P.
Name/Title:Chi Sing Ho / Authorized Signatory
Date:01/20/2026
IDG-Accel China Growth Fund III Associates L.P.
Signature:/s/ Chi Sing Ho on behalf of IDG-Accel China Growth Fund GP III Associates Ltd., General Partner of IDG-Accel China Growth Fund III Associates L.P.
Name/Title:Chi Sing Ho / Authorized Signatory
Date:01/20/2026
IDG-Accel China Growth Fund GP III Associates Ltd.
Signature:/s/ Chi Sing Ho
Name/Title:Chi Sing Ho / Authorized Signatory
Date:01/20/2026
Ho Chi Sing
Signature:/s/ Ho Chi Sing
Name/Title:Ho Chi Sing
Date:01/20/2026
Zhou Quan
Signature:/s/ Quan Zhou
Name/Title:Quan Zhou
Date:01/20/2026

FAQ

What does this Schedule 13D/A Amendment No. 7 disclose for CASI (CASI)?

This amendment updates the ownership report of IDG-Accel affiliated funds and individuals in CASI Pharmaceuticals, Inc.. It reflects changes in their percentage ownership caused by an increase in CASI’s total outstanding ordinary shares over time and confirms that each reporting person is now below the five percent beneficial ownership threshold as of September 30, 2025.

How many CASI ordinary shares do the IDG-Accel reporting persons beneficially own?

The IDG-Accel funds and related entities report beneficial ownership of 915,850 CASI ordinary shares. This total includes 855,222 ordinary shares held by IDG-Accel China Growth Fund III L.P. and 60,628 ordinary shares held by IDG-Accel China III Investors L.P., with indirect voting and dispositive power described through their general partners.

What percentage of CASI Pharmaceuticals does the IDG-Accel group’s stake represent?

The aggregate 915,850 ordinary shares beneficially owned by each reporting person correspond to 4.5% of CASI’s ordinary shares. This percentage is calculated using 20,548,273 ordinary shares outstanding as of September 30, 2025, as disclosed in CASI’s Form 6-K filed on November 14, 2025.

When did the IDG-Accel reporting persons fall below 5% ownership in CASI?

The filing states that each of the reporting persons ceased to be the beneficial owner of more than five percent of CASI’s ordinary shares on September 30, 2025. This change resulted from an increase in the total issued and outstanding ordinary shares of CASI, rather than from reported share sales by these holders.

Did the reporting persons trade CASI shares in the 60 days before this amendment?

According to the amended Item 5(c), none of the reporting persons engaged in any transactions in CASI Pharmaceuticals’ securities during the past sixty days other than as disclosed in the statement. The amendment itself focuses on updated ownership percentages rather than new purchase or sale activity.

How are voting and dispositive powers over CASI shares allocated among the IDG-Accel entities and individuals?

The filing details that IDG-Accel China Growth Fund III L.P. and IDG-Accel China III Investors L.P. hold the CASI shares, while IDG-Accel China Growth Fund GP III Associates Ltd. is the ultimate general partner of both funds and has sole voting and dispositive power over 915,850 shares. Ho Chi Sing and Quan Zhou, as directors and shareholders of this general partner, may be deemed to share voting and dispositive power over these shares, with Quan Zhou also holding options for 76,788 additional ordinary shares.

What is Quan Zhou’s total reported interest in CASI Pharmaceuticals shares?

Quan Zhou reports aggregate beneficial ownership of 992,638 CASI ordinary shares, representing 4.8% of CASI’s ordinary shares based on 20,548,273 shares outstanding as of September 30, 2025. This includes 76,788 ordinary shares issuable upon exercise of options granted by CASI, plus shared voting and dispositive power over the 915,850 shares held by the IDG-Accel funds.

Casi Pharmaceuticals Inc

NASDAQ:CASI

CASI Rankings

CASI Latest News

CASI Latest SEC Filings

CASI Stock Data

20.29M
11.64M
48.39%
20.42%
2.21%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
China
ROCKVILLE